Triple-Negative Breast Cancer (TNBC) Completed Phase 2 Trials for Erlotinib (DB00530)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00733408Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerTreatment